Get the Stockscreener App
5.27
1.31%
-0.07
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Altimmune Inc stock is traded at $5.27, with a volume of 6.35M.
It is down -1.31% in the last 24 hours and up +24.59% over the past month.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
See More
Previous Close:
$5.34
Open:
$5.395
24h Volume:
6.35M
Relative Volume:
2.07
Market Cap:
$549.88M
Revenue:
$409.00K
Net Income/Loss:
$-101.35M
P/E Ratio:
-3.2134
EPS:
-1.64
Net Cash Flow:
$-71.49M
1W Performance:
+0.57%
1M Performance:
+24.59%
6M Performance:
-26.29%
1Y Performance:
-38.65%
1-Day Range:
$5.25
$6.0299
1-Week Range:
$5.025
$6.0299
52-Week Range:
$2.90
$9.59
Altimmune Inc Stock (ALT) Company Profile
Name
Altimmune Inc
Sector
Industry
Phone
(240) 654-1450
Address
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
5.27 | 557.19M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Sell |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Nov-12-24 | Initiated | UBS | Buy |
| Apr-29-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-24-24 | Initiated | Goldman | Neutral |
| Mar-22-23 | Downgrade | Goldman | Buy → Neutral |
| Dec-01-22 | Initiated | Goldman | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-02-21 | Initiated | H.C. Wainwright | Buy |
| Feb-11-21 | Initiated | Guggenheim | Buy |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Nov-12-20 | Reiterated | B. Riley Securities | Buy |
| Sep-25-20 | Initiated | B. Riley FBR | Buy |
| Aug-14-20 | Initiated | Evercore ISI | Outperform |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jul-28-20 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-20 | Resumed | ROTH Capital | Buy |
| Jul-19-19 | Initiated | ROTH Capital | Buy |
| Oct-09-17 | Initiated | Piper Jaffray | Overweight |
View All
Altimmune Inc Stock (ALT) Latest News
Altimmune (NASDAQ:ALT) Stock Price Up 12.2%Here's Why - MarketBeat
Published on: 2025-12-14 03:05:57 - moha.gov.vn
Altimmune (ALT) Stock News, Forecasts and Analysis for Dec. 12, 2025: What Investors Are Watching Ahead of Pemvidutide Catalysts - ts2.tech
Altimmune Amends Loan Agreement with Hercules Capital - MSN
Does Altimmune (ALT) Have the Potential to Rally 229.28% as Wall Street Analysts Expect? - Yahoo Finance
Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineALT - ACCESS Newswire
Altimmune (ALT) Stock: CEO Shake-Up, Imminent MASH Data and 250% Upside Forecasts as of December 9, 2025 - ts2.tech
Altimmune Inc (HAM:3G0) Competitors 2025 - GuruFocus
Altimmune (HAM:3G0) ROA % : -36.91% (As of Sep. 2025) - GuruFocus
Altimmune (HAM:3G0) EV-to-EBIT : -4.00 (As of Dec. 08, 2025) - GuruFocus
Altimmune Inc (HAM:3G0) Stock Price, Trades & News - GuruFocus
Geode Capital Management LLC Raises Holdings in Altimmune, Inc. $ALT - MarketBeat
Altimmune: 48-Week MASH Data Due This Month Is Make Or Break For The Company (NASDAQ:ALT) - Seeking Alpha
EBITDA per share of Altimmune, Inc. – LSE:0A4C - TradingView
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down - geneonline.com
Altimmune (ALT) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Durso succeeding Garg as Altimmune CEO - BioCentury
Altimmune releases additional phase 2 pemvidutide data for MASH - MSN
Altimmune (NASDAQ:ALT) Stock Price Down 6.6%Time to Sell? - MarketBeat
Investors SueWallSt as Altimmune, Inc. Faces Securities Fraud Allegations - The National Law Review
ALT SEC FilingsAltimmune 10-K, 10-Q, 8-K Forms - Stock Titan
Altimmune Announces CEO Transition and Succession Plan - The Globe and Mail
Key facts: Altimmune appoints Jerry Durso as CEO; pemvidutide trial data pending - TradingView
Altimmune announces CEO transition - MSN
Gaithersburg drug developer Altimmune names new CEO as current chief readies exit - The Business Journals
Altimmune stock falls after CEO Garg announces 2026 departure By Investing.com - Investing.com Canada
Altimmune stock falls after CEO Garg announces 2026 departure - Investing.com
Altimmune, Inc. Announces CEO Changes - marketscreener.com
Altimmune CEO Vipin Garg to Step Down - marketscreener.com
Altimmune names Jerry Durso as new CEO effective January 2026 By Investing.com - Investing.com Canada
Altimmune, Inc. Announces CEO Transition - TradingView
Altimmune names Jerry Durso as new CEO effective January 2026 - Investing.com
Altimmune (ALT) Announces CEO Transition Plan - GuruFocus
Altimmune falls as CEO Vipin Garg to step down - TradingView
Altimmune announces leadership change as CEO Vipin Garg steps down - Traders Union
Altimmune, Inc. Announces CEO Transition as Jerry Durso Succeeds Vipin Garg, Ph.D. - Quiver Quantitative
Altimmune announces CEO transition, succession plan - marketscreener.com
Altimmune Announces CEO Transition, Succession Plan - TradingView — Track All Markets
Altimmune (Nasdaq: ALT) details CEO handover and late-stage pemvidutide path in MASH - Stock Titan
Intech Investment Management LLC Purchases 73,482 Shares of Altimmune, Inc. $ALT - MarketBeat
Altimmune Investors Drop Suit Over Liver Drug Trial, Stock Drop - Bloomberg Law News
Altimmune, Inc. (NASDAQ:ALT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Altimmune (Nasdaq: ALT) to Present Chat at Piper Sandler 37th Healthcare Conference - Stock Titan
Wall Street Analysts Predict a 250.59% Upside in Altimmune (ALT): Here's What You Should Know - MSN
Altimmune Target of Unusually Large Options Trading (NASDAQ:ALT) - MarketBeat
ALT Stock Today (November 25, 2025): Altimmune Extends Rally as Pemvidutide Nears Critical FDA Moment - ts2.tech
Altimmune’s RECLAIM STUDY: A New Hope for Alcohol Use Disorder Treatment - MSN
Altimmune’s RESTORE TRIAL: A Promising Step in ALD Treatment - MSN
Net debt of Altimmune, Inc. – HAM:3G0 - TradingView
Altimmune Stock Attracts Strong Retail Buzz As Investors Count Down To 48-Week Data For Its Fatty Liver Treatment - MSN
Altimmune Inc Stock (ALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):